L
Luke Bamber
Researcher at Bayer HealthCare Pharmaceuticals
Publications - 18
Citations - 833
Luke Bamber is an academic researcher from Bayer HealthCare Pharmaceuticals. The author has contributed to research in topics: Rivaroxaban & Population. The author has an hindex of 9, co-authored 16 publications receiving 686 citations. Previous affiliations of Luke Bamber include University of Plymouth.
Papers
More filters
Journal ArticleDOI
Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study.
TL;DR: An observational cohort study was undertaken to estimate the incidence of first and recurrent venous thromboembolism in patients with active cancer, finding rates were similar after initial pulmonary embolism and after initial deep-vein thrombosis.
Journal ArticleDOI
Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer
TL;DR: VTE is common and associated with high recurrence rates, and effort is required to prevent VTE and to reduce recurrences.
Journal ArticleDOI
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Bonno van Bellen,Luke Bamber,Francine Correa de Carvalho,Martin H. Prins,Maria Wang,Anthonie W. A. Lensing +5 more
TL;DR: The phase III Einstein DVT and EinSTEIN PE trials demonstrated the potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) as mentioned in this paper.
Journal ArticleDOI
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis
Luke Bamber,Maria Y. Wang,Martin H. Prins,Cathleen Ciniglio,Rupert Bauersachs,Anthonie W. A. Lensing,Stefan J. Cano +6 more
TL;DR: Rivaroxaban results in improved treatment satisfaction compared with enoxaparin/VKA among patients with DVT, particularly in reducing patient-reported anticoagulation burden.
Journal ArticleDOI
The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients
TL;DR: Both the ACTS Burdens and ACTS Benefits scales consistently satisfied traditional reliability and validity criteria across multiple language datasets, supporting it as a clinically useful patient-reported instrument of satisfaction with anticoagulant treatment in clinical trials.